The Front Room — a clinical regulatory commons
RSS
← Back to feed

Ryaltris pediatric expansion cleared for ages 6-12

Sponsor
Glenmark Specialty S.A.
Drug
Ryaltris · olopatadine hydrochloride / mometasone furoate
Indication
Allergic rhinitis
More on Glenmark Specialty S.A. Google News

FDA approves expanded use of Ryaltris nasal spray for children aged 6 to less than 12 years.

What this means

Ryaltris is a nasal spray combining an antihistamine and a steroid to treat seasonal allergy symptoms like sneezing and congestion. The FDA has now approved its use for children as young as six years old. This gives younger kids a single, convenient spray option for managing their seasonal allergies.

Read original at accessdata.fda.gov
Topic Pediatric Indication

Drug Watch — recent news on Ryaltris